These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18799806)

  • 21. Deletion of Abcg2 has differential effects on excretion and pharmacokinetics of probe substrates in rats.
    Huang L; Be X; Tchaparian EH; Colletti AE; Roberts J; Langley M; Ling Y; Wong BK; Jin L
    J Pharmacol Exp Ther; 2012 Nov; 343(2):316-24. PubMed ID: 22869929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.
    Do TM; Noel-Hudson MS; Ribes S; Besengez C; Smirnova M; Cisternino S; Buyse M; Calon F; Chimini G; Chacun H; Scherrmann JM; Farinotti R; Bourasset F
    J Alzheimers Dis; 2012; 30(1):155-66. PubMed ID: 22391220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.
    Polli JW; Baughman TM; Humphreys JE; Jordan KH; Mote AL; Webster LO; Barnaby RJ; Vitulli G; Bertolotti L; Read KD; Serabjit-Singh CJ
    Drug Metab Dispos; 2004 Jul; 32(7):722-6. PubMed ID: 15205387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression and transport activity of breast cancer resistance protein (Bcrp/Abcg2) in dually perfused rat placenta and HRP-1 cell line.
    Staud F; Vackova Z; Pospechova K; Pavek P; Ceckova M; Libra A; Cygalova L; Nachtigal P; Fendrich Z
    J Pharmacol Exp Ther; 2006 Oct; 319(1):53-62. PubMed ID: 16809480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo inhibition of BCRP/ABCG2 mediated transport of nitrofurantoin by the isoflavones genistein and daidzein: a comparative study in Bcrp1 (-/-) mice.
    Merino G; Perez M; Real R; Egido E; Prieto JG; Alvarez AI
    Pharm Res; 2010 Oct; 27(10):2098-105. PubMed ID: 20607366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
    Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.
    Agarwal S; Sane R; Gallardo JL; Ohlfest JR; Elmquist WF
    J Pharmacol Exp Ther; 2010 Jul; 334(1):147-55. PubMed ID: 20421331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin.
    Chen WS; Luker KE; Dahlheimer JL; Pica CM; Luker GD; Piwnica-Worms D
    Biochem Pharmacol; 2000 Aug; 60(3):413-26. PubMed ID: 10856437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
    Kruijtzer CM; Beijnen JH; Rosing H; ten Bokkel Huinink WW; Schot M; Jewell RC; Paul EM; Schellens JH
    J Clin Oncol; 2002 Jul; 20(13):2943-50. PubMed ID: 12089223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Mol Pharm; 2012 Nov; 9(11):3236-45. PubMed ID: 23020847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells.
    Xia CQ; Liu N; Yang D; Miwa G; Gan LS
    Drug Metab Dispos; 2005 May; 33(5):637-43. PubMed ID: 15716365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey.
    Ward KW; Azzarano LM
    J Pharmacol Exp Ther; 2004 Aug; 310(2):703-9. PubMed ID: 15056727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs.
    Matsson P; Pedersen JM; Norinder U; Bergström CA; Artursson P
    Pharm Res; 2009 Aug; 26(8):1816-31. PubMed ID: 19421845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stereoselective interaction of pantoprazole with ABCG2. II. In vitro flux analysis.
    Wang L; Leggas M; Empey PE; McNamara PJ
    Drug Metab Dispos; 2012 May; 40(5):1024-31. PubMed ID: 22355035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat.
    Zamek-Gliszczynski MJ; Hoffmaster KA; Humphreys JE; Tian X; Nezasa K; Brouwer KL
    J Pharmacol Exp Ther; 2006 Oct; 319(1):459-67. PubMed ID: 16857726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
    Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
    J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Local Drug-Drug Interaction of Donepezil with Cilostazol at Breast Cancer Resistance Protein (ABCG2) Increases Drug Accumulation in Heart.
    Takeuchi R; Shinozaki K; Nakanishi T; Tamai I
    Drug Metab Dispos; 2016 Jan; 44(1):68-74. PubMed ID: 26467765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatobiliary disposition of 3alpha,6alpha,7alpha,12alpha-tetrahydroxy-cholanoyl taurine: a substrate for multiple canalicular transporters.
    Megaraj V; Iida T; Jungsuwadee P; Hofmann AF; Vore M
    Drug Metab Dispos; 2010 Oct; 38(10):1723-30. PubMed ID: 20643783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
    Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH
    Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.